52results about How to "Reduce risk of recurrence" patented technology

In this application are described chimeric, humanized, affinity matured, stability enhanced, and bispecific Anti-GD2 antibodies and fragments thereof. Also provided are methods of using individual antibodies or compositions thereof for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.

The invention provides methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.

The invention discloses a method for harmless treatment of ferment antibiotic fungus residues. The method includes: subjecting the ferment antibiotic fungus residues to ultrahigh-temperature intensive acidogenic fermentation treatment; performing biochemical treatment on the fungus residues subjected to ultrahigh-temperature intensive acidogenic fermentation treatment. Thermophilic hydrolysis acidogenic bacteria are adopted for high-temperature anaerobic acidogenic fermentation treatment of the ferment antibiotic fungus residues, the fungus residues are hydrolyzed and acidized, antibiotic producing strains in the fungus residues are inactivated, residual antibiotics are degraded prior to biochemical treatment, and accordingly harmless treatment and recycling of the antibiotic fungus residues are realized. By adoption of the method, the antibiotic producing strains in the fungus residues subjected to harmless treatment are completely killed, antibiotic residues are avoided, and the fungus residues subjected to biochemical treatment is free of dangers caused by drug-resistant fungi and drug-resistant genes. The method has advantages that efficiency in harmless treatment of the antibiotic fungus residues is improved, environment protection is benefited, hazardous wastes are recycled, and remarkable economic benefits and social benefits are achieved.

The invention discloses a use of a recombinant mesenchymal stem cell in preparation of an immunosuppressant. The invention relates to the recombinant mesenchymal stem cell capable of expressing a chemokine receptor CCR7 on a cytomembrane. After infusion, the recombinant mesenchymal stem cells can be specifically transferred to a secondary lymphatic organ, and a large amount of the recombinant mesenchymal stem cells are gathered in a T cell enrichment region in the secondary lymphatic organ and can efficiently inhibit T cell immunoreaction. Through use of the recombinant mesenchymal stem cell in treatment on graft-versus-host disease after bone marrow transplantation, immunological rejection after organ transplantation and autoimmune diseases, a cost is reduced, a cell use amount is reduced and side-effects are relieved. In treatment, the recombinant mesenchymal stem cell retains tumor cell killing effects and provides a high efficiency and beneficial novel approach for clinical treatment on graft-versus-host disease after bone marrow transplantation, immunological rejection after organ transplantation and autoimmune diseases of tumor high-risk groups.

Methods and compositions for treating inflammatory bowel disease, irritable bowel syndrome, and travelers' diarrhea involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic. The practice of the invention may reduce or eliminate the use of immunosuppressants and other drugs in the treatment and management of inflammatory bowel disease, irritable bowel syndrome, travelers' diarrhea, and hepatic encephalopathy.

Methods and compositions for treating inflammatory bowel disease involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic. The practice of the invention may reduce or eliminate the use of immunosuppressants in the treatment and management of IBD.

The invention discloses a thyroid disease prediction modeling method based on an association decision tree. An associated decision tree MsaDtd algorithm is provided, composite features are fully utilized, and an original feature space is converted into a larger disease diagnosis feature space to predict the LNM of a PTMC patient; and fuzzy logic is introduced to process continuous attributes, so that the cost of generating a large number of frequent items is avoided, and the robustness and generalization ability of the model are improved. According to the method, a clinician can use information provided by the prediction model, a specific treatment scheme is adopted in the whole treatment process, and the clinician should take targeted intervention measures to patients prone to LNM, so that help is provided for reducing the risk of cancer recurrence.

The invention belongs to the field of tumor biological products, in particular to a chimeric antigen receptor and its gene and a recombinant expression vector, CD19-CD20 dual targeting T cells and anapplication thereof. The chimeric antigen receptor is CD20ScFv-L-CD19ScFv-CD8-CD137-CD3 zeta, which includes CD20ScFv, ligation peptide L, CD19ScFv, a hinge region and a transmembrane region of CD8, an intracellular signal domain of CD137, and an intracellular signal domain of CD3 zeta which are connected in series in order. In the treatment of B cell line hematological malignancy, the chimeric antigen receptor-modified T cells of the present invention can not only specifically recognize tumor cells expressed by a single target of CD19 antigen or CD20 antigen, but also to recognize tumor cellsco-expressed by two targets of CD19 antigen and CD20 antigen, compared with single target CAR T, dual-target CAR T has stronger anti-tumor activity, which avoids immune escape of tumor cells with lowabundance antigen expression, and the risk of recurrence is reduced.

The present invention relates to a method for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to a pediatric ALL patient in the need thereof.

The invention discloses a pretreatment method of ferment antibiotic fungi residues. The pretreatment method comprises ultrahigh temperature reinforced acidogenic fermentation treatment of the ferment antibiotic fungi residues. Thermophilic hydrolysis acid-forming bacteria are used for performing high temperature anaerobic digestion treatment on the ferment antibiotic fungi residues, so that the fungi residues are hydrolyzed and acidified, antibiotic producing bacteria in the fungi residues are inactivated, and retained antibiotics are degraded. The fungi residues pretreated through the method can be directly subjected to subsequent biochemical treatment after being subjected to antibiotic removal. According to the method disclosed by the invention, the antibiotic producing bacteria can be completely killed, the antibiotics in the fungi residues can be removed, inhibition of high-concentration antibiotics to microorganisms is reduced, the difficulty in treatment of the fungi residues based on the subsequent biochemical method is reduced, generation of drug-resistant fungi and drug-resistant genes in the subsequent biochemical treatment is reduced, the harmless treatment efficiency of the antibiotic fungi residues is improved, and environmental protection is facilitated.

The invention relates to the technical field of nano biomedical materials, and particularly discloses a novel long-acting degradable biological nano membrane slowing releasing VEGF and bFGF and a preparation method of the nano membrane. The nanofiber membrane obtained by the method of the invention has the following characteristics: 1, The nano membrane is non-toxic to human tissues, does not produce harmful substances after degradation in the body, and has good biocompatibility; 2, the nano membrane can avoid the inactivation of growth factors by organic solvents, strong acids and alkalis, high temperature and other factors, ensures that the growth factors loaded on the membrane maintain good activity and has a best therapeutic effect; and 3, the nano membrane avoids trauma caused by direct injection of growth factors into a ventricle and the problem of uncontrollable concentration, has a good effect of promoting vascular and nerve regeneration, can be applied to insufficient vascularregeneration after indirect vascular bypass surgery in neurosurgery, improves the therapeutic effect of related ischemic cerebrovascular diseases, and reduces the risk of recurrence of ischemic stroke.

The invention discloses a chimeric antigen receptor capable of secreting a bispecific antibody as well as an expression vector and an application thereof, which belong to the field of tumor immune drugs. The chimeric antigen receptor comprises a signal peptide, a CD19-targeting single-chain antibody, a lengthened CD8 alpha hinge region, a transmembrane region, a costimulatory factor, an intracellular signal peptide, a P2A connecting peptide, an IL2 signal peptide, a CD20-targeting single-chain antibody, a CD3-targeting single-chain antibody and a tag protein which are connected in sequence. The chimeric antigen receptor is the bispecific antibody capable of specifically targeting CD19 positive tumor cells and secreting targeting CD20 and targeting CD3 at the same time, the non-conductive Tcells can be targeted and activated, so that the tumor antigen CD20 is targeted, and the purpose that the CAR-T cells effectively kill malignant blood tumor cells of a B cell line in vivo is achieved. Meanwhile, the T cells of the chimeric antigen receptor can prevent CD19 positive tumor cells with low abundance expression from generating immune escape, so that the recurrence risk of malignant blood tumors of a B cell line is reduced.

Pharmaceutical formulations comprising: a compound selected from the group consisting of ziprasidone, having a maximum average particle size; a carrier; and preferably at least two surface stabilizers are disclosed. The present invention also comprises methods of treating psychosis with such a formulation and processes for making such a formulation.

The invention discloses a method for establishing a cerebral apoplexy recurrence prediction model. The method comprises the steps of 1, establishing a comparison database; 2, establishing a cerebral apoplexy recurrence prediction system; and 3, integrating the comparison database established in the step 1 into an intelligent analysis module. The invention further discloses a cerebral apoplexy recurrence prediction device which comprises a computer, a heart rate tester, a blood pressure measuring instrument, an oximeter, a thermometer and a blood lipid instrument; the computer comprises a host,a display, a keyboard and a mouse; a cerebral apoplexy recurrence prediction model is installed in the host, and the display, the keyboard and the mouse are electrically connected with the host through data lines. The method and the device are proposed for elderly patients of 75 years old or above, are suitable for hospitals and families, can avoid troubles caused by the fact that the elderly patients need to frequently perform cerebral apoplexy recurrence prediction, solve life troubles, effectively guarantee the life rhythm of the elderly patients, and further improve the life quality of the elderly patients.

Methods of treatment using a high oral dose of an interferon are described. An interferon, such as interferon-alpha, interferon-beta, or interferon-tau, is administered to persons afflicted with an autoimmune condition, a viral infection, or a condition of cellular proliferation.

The invention discloses that ER-negative breast cancers can be converted into ER positive breast cancers, such as to a breast cancer of luminal-like phenotype by treatment with anti-PDGF-CC antibodies. ER-positive breast cancers, including luminal-like breast cancers can be treated with anti-estrogen treatment. On this basis the invention discloses that surprisingly, ER-negative breast cancers can be treated with anti-estrogen treatment, if the treatment is combined with treatment with anti-PDGF-CC antibodies. Said treatment may for example be an adjuvant treatment, for example a treatment aiming at reducing the risk of relapse of a breast cancer after removal of the primary tumor by surgery.

The invention discloses a Chinese medicament formula for treating arthritis. The Chinese medicament formula is characterized by comprising the following ingredients by weight: 150 to 200 grams of prepared rhubarb, 20 to 30 grams of Japanese honeysuckle stem, 15 to 20 grams of ovientvine, 15 to 20 grams of medicinal cyathula root, 10 to 15 grams of amur cork tree bark, 10 to 15 grams of cortex moutan, 15 to 20 grams of angelica root, 15 to 20 grams of licorice, 10 to 15 grams of Chinese angelica, and 10 to 15 grams of suberect spatholobus stem. Through the medicinal value of each ingredient and the effects among the ingredients in the Chinese medicament formula, the Chinese medicament formula has a good curative effect of treating the arthritis, dose not cause any toxic or side effect on patients, and is low in cost and less in risk.